{
    "organizations": [],
    "uuid": "ad977f89aaf8de973f754254f612bcdba4fdfbde",
    "author": "",
    "url": "https://www.reuters.com/article/brief-evofem-biosciences-receives-fast-t/brief-evofem-biosciences-receives-fast-track-designation-for-amphora-for-prevention-of-chlamydia-idUSFWN1QB0HH",
    "ord_in_thread": 0,
    "title": "BRIEF-Evofem Biosciences Receives Fast Track Designation For Amphora For Prevention Of Chlamydia",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 21, 2018 / 12:05 PM / in 12 minutes BRIEF-Evofem Biosciences Receives Fast Track Designation For Amphora For Prevention Of Chlamydia Reuters Staff Feb 21 (Reuters) - Evofem Biosciences Inc: * EVOFEM BIOSCIENCES RECEIVES FAST TRACK DESIGNATION FOR AMPHORA FOR PREVENTION OF CHLAMYDIA * EVOFEM BIOSCIENCES INC - DATA FROM AMPHORA PHASE 3 TRIAL IS EXPECTED IN Q1 OF 2019 Source text for Eikon: Further company coverage:",
    "published": "2018-02-21T14:02:00.000+02:00",
    "crawled": "2018-02-21T14:21:40.015+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "minute",
        "bioscience",
        "receives",
        "fast",
        "track",
        "designation",
        "amphora",
        "prevention",
        "chlamydia",
        "reuters",
        "staff",
        "feb",
        "reuters",
        "evofem",
        "bioscience",
        "inc",
        "evofem",
        "bioscience",
        "receives",
        "fast",
        "track",
        "designation",
        "amphora",
        "prevention",
        "chlamydia",
        "evofem",
        "bioscience",
        "inc",
        "data",
        "amphora",
        "phase",
        "trial",
        "expected",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}